Search Results

1 - 10 of 17 items :

  • pharmacokinetics x
  • Life Sciences x
  • Clinical Medicine x
  • Internal Medicine x
Clear All
Effect of letrozole on spermogram parameters and hormonal profile in infertile men: A clinical trial study

. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 98, 48–51, 2012. Haider H, Solanki KS, Pal G, Singh MK, Kothari JS, Agarwal VK. Process for the preparation of letrozole. WO/2007/054964, PCT/IN2006/000337, 2007. https://patentscope.wipo.int › search › detail. Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs LJ, Jones A, Powles T, Stein R, Coombes RC. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3

Open access
Vildagliptin in the Treatment of Type 2 Diabetes Mellitus

References 1. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986. 2. Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin- dependent) diabetes. Diabetologia 29: 46-52, 1986. 3. Vildagliptin - summary of product characteristics, 2012. 4. He Y-L. Clinical pharmacokinetics and pharmacodynamics of

Open access
Exenatide QW – New Perspectives 5 Years after its First Use

receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 19: 524-536, 2017. 7. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 18:359-367, 2009. 8. Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 18: 555-571, 2017. 9. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or

Open access
Gender and Contractile Functions of Slow and Fast Skeletal Muscles in Streptozotocin Induced Diabetic Sprague Dawley Rats

.1155/2010/931903, 2010. 14. Eng CM, Smallwood LH, Rainiero MP, Lahey M, Ward SR, Lieber RL. Scaling of muscle architecture and fiber types in the rat hindlimb. J Exp Biol 211: 2336-2345, 2008. 15. Hu N, Xie S, Liu L et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39: 419-425, 2011. 16. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J

Open access
Are Obese Women a Risk Group for Vitamin B12 and Folic Acid Deficiencies ?

. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49: 71-87, 2010. 24. Zhou SS, Li D, Chen NN, Zhou Y. Vitamin paradox in obesity: Deficiency or excess? World J Diabetes 6: 1158-1167, 2015. 25. Bird JK, Ronnenberg AG, Choi SW, Du F, Mason JB, Liu Z. Obesity is associated with increased red blood cell folate despite lower dietary intakes and serum concentrations. J Nutr 145: 79-86, 2015. 26. Pfeiffer CM, Sternberg MR, Fazili Z et al. Folate status and concentrations of serum folate forms in the US population

Open access
Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30, 239–245, 1981. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 46, 1179–1187, 2006. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes

Open access
Adverse eff ects of polymeric nanoparticle poly(ethylene glycol)- block-polylactide methyl ether (PEG-b-PLA) on steroid hormone secretion by porcine granulosa cells

drug carriers. Adv Clin Exp Med 24, 749-758, 2015. Oberdoster G. Safety assessment for nanotechnology and nanomedicine: concept of nanotoxicology. J Intern Med 267, 89-105, 2009. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 163, 93-99, 2012. Pelham RW, Nix LC, Chavira RE, Cleveland MVB, Stetson P. Clinical trial: si ngle- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in young and elderly subjects. Aliment

Open access
Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych

Robak T Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly Expert Opin Drug Metab Toxicol 2015 11 1371 91 [11] Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59. 21094089 10.1016/S1470-2045(10)70261-8 Wilson WH O’Connor OA Czuczman MS et al Navitoclax, a targeted high

Open access
Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum

, Barlow KB, Nobrega JN, Kapur S. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14, 1165–1178, 2011. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl 13), 5–11, 2002. Nomikos GG, Tham CS, Fibiger HC, Svensson TH. The puta in rat medial prefrontal cortex and lateral tive atypical antipsychotic drug amperozide preferentially increases c-fos expression septum

Open access
Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease

pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [ 16 ]. Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [ 76 ]. However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [ 58 ]. Studies in animal models revealed that that HU therapy inhibits spermatogenesis

Open access